{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+B-+Part+1", "query": { "intervention": "Treatment B- Part 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1108, "total_pages": 111, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Treatment+B-+Part+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T21:09:20.802Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05973773", "title": "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2023-12-18", "completion_date": "2027-05-27", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 9, "location_summary": "Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more", "locations": [ { "city": "Henderson", "state": "Nevada" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05973773" }, { "nct_id": "NCT00957905", "title": "Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Extragonadal Seminoma", "Recurrent Malignant Extragonadal Germ Cell Tumor", "Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Ovarian Germ Cell Tumor", "Stage III Testicular Cancer", "Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor", "Stage IV Extragonadal Seminoma", "Stage IV Ovarian Germ Cell Tumor" ], "interventions": [ { "name": "Alvocidib Hydrochloride", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2009-06", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-03-10", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 10, "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 6 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00957905" }, { "nct_id": "NCT06345755", "title": "A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Autosomal Dominant Polycystic Kidney Disease (ADPKD)" ], "interventions": [ { "name": "VX-407", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 159, "start_date": "2024-04-17", "completion_date": "2025-06-13", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06345755" }, { "nct_id": "NCT05616793", "title": "Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "LCA5" ], "interventions": [ { "name": "AAV8.hLCA5", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Opus Genetics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 22, "start_date": "2023-06-15", "completion_date": "2028-06-15", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05616793" }, { "nct_id": "NCT04292730", "title": "Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Remdesivir", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1113, "start_date": "2020-03-15", "completion_date": "2020-06-26", "has_results": true, "last_update_posted_date": "2021-01-26", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 106, "location_summary": "Anaheim, California • Berkeley, California • Burlingame, California + 76 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04292730" }, { "nct_id": "NCT02968121", "title": "Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Brexpiprazole, OPDC-34712", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 22, "start_date": "2017-01", "completion_date": "2017-12-14", "has_results": false, "last_update_posted_date": "2018-01-12", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 2, "location_summary": "Garden Grove, California • San Diego, California", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02968121" }, { "nct_id": "NCT07129993", "title": "Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Urothelial Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-09-26", "completion_date": "2030-01-22", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 38, "location_summary": "Fullerton, California • Glendale, California • La Jolla, California + 34 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07129993" }, { "nct_id": "NCT02908685", "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Muscular Atrophy, Spinal" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Risdiplam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 231, "start_date": "2016-10-19", "completion_date": "2023-10-02", "has_results": true, "last_update_posted_date": "2024-04-24", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 2, "location_summary": "Palo Alto, California • New York, New York", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02908685" }, { "nct_id": "NCT05462106", "title": "A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Amyloid Plaque", "Beta-Amyloid", "DSAD", "Prodromal Alzheimer's Disease", "Alzheimer's Disease" ], "interventions": [ { "name": "Placebo (Study Part 1a)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose A in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose B in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose C in Study Part 1a", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b", "type": "BIOLOGICAL" }, { "name": "Placebo (Study Part 2)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose A in Study Part 2", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose B in Study Part 2", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 at Dose C in Study Part 2", "type": "BIOLOGICAL" }, { "name": "Placebo (Study Part 1b)", "type": "BIOLOGICAL" }, { "name": "ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AC Immune SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "35 Years to 85 Years" }, "enrollment_count": 304, "start_date": "2022-06-21", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Lady Lake", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "The Villages", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462106" }, { "nct_id": "NCT00103285", "title": "Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Childhood B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "9 Years", "sex": "ALL", "summary": "1 Year to 9 Years" }, "enrollment_count": 5377, "start_date": "2005-04-11", "completion_date": "2021-03-31", "has_results": true, "last_update_posted_date": "2021-06-14", "last_synced_at": "2026-09-06T21:09:20.802Z", "location_count": 210, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103285" } ] }